Beyond proof-of-concept: Validating robust automated diffuse lower-grade glioma segmentation for clinical applications in longitudinal follow-up

超越概念验证:验证稳健的自动化弥漫性低级别胶质瘤分割方法在纵向随访临床应用中的有效性

阅读:1

Abstract

BACKGROUND: Monitoring diffuse lower-grade glioma (DLGG) evolution on MRI is challenging due to their infiltrative nature and post-surgical deformations. The RANO criteria recommend assessing the 2D tumor size, but volume analysis remains the gold standard for calculating growth rate. Manual tumor segmentation, however, is time-consuming, limiting its use in clinical practice. Automated segmentation tools like nnU-Net are promising but require clinical validation. METHODS: We used 1971 MRI exams from 207 DLGG patients to train and validate an in house-developed nnU-Net al.orithm. The dataset included scans from various MRI systems, with 2D and 3D FLAIR and T1-weighted acquisitions, that were divided into derivation (N = 1771) and validation (N = 200) sets with matching 2D and 3D FLAIR ratios. The algorithm's automated segmentations (AS) were compared with manual segmentations (MS) by expert neuroradiologists using the dice similarity coefficient (DSC) and Intersection over Union (IoU). Tumor volume and mean tumor diameter (MTD) were compared using Lin's concordance correlation coefficient (CCC) and Bland-Altman tests. RESULTS: The median nnU-Net DSC and IoU were 0.93 and 0.86, respectively. In the validation cohort, 64% of exams had excellent (≥0.9), 31% good ([0.7-0.9]), 3.5% unsatisfactory ([0.5-0.7]), and 1.5% poor DSC (<0.5). Higher DSC correlated with larger tumor volumes (P < .001). Tumor volume and MTD showed near-perfect concordance between AS and MS (CCC: 0.991 and 0.989, respectively). CONCLUSIONS: Our automated nnU-Net segmentation tool demonstrates high accuracy and potential for clinical integration, enhancing DLGG monitoring and management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。